RT Journal Article
T1 Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
A1 Santos Garcia, Diego
A1 Fernandez Pajarin, Gustavo
A1 Oropesa-Ruiz, Juan Manuel
A1 Escamilla Sevilla, Francisco
A1 Rahim Lopez, Raul Rashid Abdul
A1 Muñoz Enriquez, Jose Guillermo
K1 Parkinson’s disease
K1 effectiveness
K1 non-motor symptoms
K1 open-label study
K1 opicapone
AB Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p
PB MDPI AG
SN 2076-3425
YR 2022
FD 2022-03-10
LK http://hdl.handle.net/10668/20851
UL http://hdl.handle.net/10668/20851
LA en
NO Santos García D, Fernández Pajarín G, Oropesa-Ruiz JM, Escamilla Sevilla F, Rahim López RRA, Muñoz Enríquez JG. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. Brain Sci. 2022 Mar 12;12(3):383.
DS RISalud
RD Apr 11, 2025